Medroxyprogesterone Acetate in Cancer Cachexia

  • Giorgio Lelli
  • Benedetta Urbini
  • Daniela Scapoli
  • Germana Gilli


For a long time the use of testosterone-derivative drugs (nandrolone decanoate and others) has been indicated for patients with cancer anorexiacachexia syndrome (CACS) on the basis of a truly protein anabolic effect [1], but the above drugs have a limited use because of some severe sideeffects (liver damage, endocrine effects).


Cancer Cachexia Medroxyprogesterone Acetate Nandrolone Decanoate Advanced Lung Adenocarcinoma Urinary Nitrogen Excretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kochakian CD (1976) II Metabolic effects. In: Kochakian CD (ed) Anabolic Steroids. Springer Verlag, Berlin, pp 5–72Google Scholar
  2. 2.
    Mantovani G, Macciò A, Massa E, Madeddu C (2001) Managing cancer-related anorexia/cachexia. Drugs 61:499–514PubMedCrossRefGoogle Scholar
  3. 3.
    Pannuti F, Martoni A, Camaggi CM et al (1982) High dose medroxyprogesterone acetate in oncology. History, clinical use and pharmacokinetics In: Cavalli F, McGuire WL, Pannuti F (eds) Proceedings of the International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Amsterdam, pp 5–43Google Scholar
  4. 4.
    Pannuti F, Burroni P, Fruet F et al (1980) Anabolizing and antipain effect of the short-term treatment with medroxyprogesterone acetate (MAP) at high oral doses in oncology. Panminerva Med 22:149PubMedGoogle Scholar
  5. 5.
    Lelli G, Angelelli B, Giambiasi ME et al (1983) The anabolic effect of high dose medroxyprogesterone acetate in oncology. Pharmacol Res Commun 15:561–568PubMedCrossRefGoogle Scholar
  6. 6.
    Lelli G, Angelelli B, Zanichelli L et al (1984) The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patients. Chemioterapia 3:327–329PubMedGoogle Scholar
  7. 7.
    Mantovani G, Macciò A, Lai P et al (1998) Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 25(Suppl 6):45–52PubMedGoogle Scholar
  8. 8.
    Kurebayashi J, Yamamoto S, Otsuki T et al (1999) Medroxyprogesterone acetate inhibits interleukin 6 secretion from KPL-4 human breast cancer cells both in vitro and in vivo: a possible mechanism of the anticachectic effect. Br J Cancer 79:631–636PubMedCrossRefGoogle Scholar
  9. 9.
    Downer S, Joel S, Albright A et al (1993) A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 67:1102–1105PubMedGoogle Scholar
  10. 10.
    Kornek GV, Schenk T, Ludwig H et al (1996) Placebo-controlled trial of medroxyprogesterone acetate in gastrointestinal malignancies and cachexia. Onkologie 19:164–168CrossRefGoogle Scholar
  11. 11.
    Neri B, Garosi VL, Intini C (1997) Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs 8:459–465PubMedCrossRefGoogle Scholar
  12. 12.
    Simons J, Aaronson NK, Vansteenkiste JFetal (1996) Effects of medroxyprogesterone acetate on appetite, weight and quality of life in advanced stage non hormone sensitive cancer: a placebo controlled multicenter study. J Clin Oncol 14:1077–1084PubMedGoogle Scholar
  13. 13.
    Simons JP, Schols AM, Hoefnagels JM et al (1988) Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer. Cancer 82:553–560CrossRefGoogle Scholar
  14. 14.
    Gagnon B, Bruera E (1998) A review of the drug treatment of cachexia associated with cancer. Drugs 55:675–688PubMedCrossRefGoogle Scholar
  15. 15.
    Maltoni M, Nanni O, Scarpi E et al (2001) High-dose progestins for the treatment of cancer anorexiacachexia syndrome. A systematic review of randomized clinical trials. Ann Oncol 12:289–300PubMedCrossRefGoogle Scholar
  16. 16.
    Cerchietti LC, Navigante AH, Peluffo GD et al (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27:85–95PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2006

Authors and Affiliations

  • Giorgio Lelli
    • 1
  • Benedetta Urbini
    • 1
  • Daniela Scapoli
    • 1
  • Germana Gilli
    • 1
  1. 1.Department of Oncology-Pathology, Clinical Oncology UnitUniversity Hospital of FerraraFerraraItaly

Personalised recommendations